Related Experiment Videos
Erythropoietin treatment in children with renal failure
R Van Damme-Lombaerts1, J Herman
1Department of Paediatrics, University Hospital, Leuven, Belgium. Rita.Lombaerts@uz.kuleuven.ac.be
Insights
Recombinant human erythropoietin (rHuEPO) effectively treats anemia in children with end-stage renal disease, improving quality of life. Careful monitoring for hypertension and addressing iron deficiency are crucial for optimal outcomes.
Area of Science:
- Pediatric Nephrology
- Hematology
- Pharmacology
Background:
- Anemia is a common complication in children with end-stage renal disease (ESRD).
- Erythropoietin (EPO) stimulates red blood cell production and is a cornerstone of anemia management in ESRD.
- Recombinant human erythropoietin (rHuEPO) offers a safe and effective therapeutic option.
Purpose of the Study:
- To evaluate the efficacy and safety of rHuEPO in pediatric patients with ESRD.
- To determine optimal hemoglobin targets for improving quality of life in anemic children with ESRD.
- To identify common challenges and side effects associated with rHuEPO therapy in this population.
Main Methods:
- Subcutaneous or intravenous administration of rHuEPO based on dialysis modality (predialysis, peritoneal dialysis, hemodialysis, post-transplant).
- Target hemoglobin levels set between 10-11 g/dl for optimal quality of life.
- Monitoring for common causes of rHuEPO non-response (iron deficiency, infections, hyperparathyroidism) and side effects (hypertension).
Main Results:
- rHuEPO is beneficial and safe across various stages of pediatric ESRD, including predialysis, dialysis, and post-transplantation.
- Subcutaneous administration is preferred for predialysis, peritoneal dialysis, and post-transplant patients, while IV administration is favored for hemodialysis.
- Iron deficiency, infections, and hyperparathyroidism are frequent causes of inadequate response to rHuEPO.
- Hypertension is the most common adverse effect, necessitating careful monitoring.
Conclusions:
- rHuEPO therapy significantly improves anemia and quality of life in children with ESRD.
- Optimizing iron status and managing comorbidities are essential for successful rHuEPO treatment.
- While rHuEPO does not directly enhance growth, its use is compatible with growth hormone therapy.
Abstract:
Erythropoietin (EPO) treatment dramatically changes the life of a child with end-stage renal disease. The administration of recombinant human (rHu)EPO is beneficial and safe in the predialysis period, during hemodialysis or peritoneal dialysis, and after renal transplantation. The goal of hemoglobin correction should be the level at which normal quality of life is possible without adverse events: in children this is usually 10-11 g/dl. rHuEPO is administered once to twice a week subcutaneously to children before dialysis, during peritoneal dialysis, and after transplantation. There is no real benefit of intraperitoneal administration. In children on hemodialysis two to three times a week IV administration is preferred. Among the many reasons for non-response to rHuEPO, iron deficiency (absolute or functional), infections, and hyperparathyroidism are the most common in the pediatric renal patient. Hypertension is the most-frequent side effect of rHuEPO treatment and needs careful monitoring. Iron should be supplemented orally or IV. No significant beneficial effect of rHuEPO on growth has been demonstrated. However, the association with recombinant human growth hormone therapy is not detrimental in children.